Literature DB >> 11059815

Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000).

L F Eng1, R S Ghirnikar, Y L Lee.   

Abstract

It is now well established that the glial fibrillary acidic protein (GFAP) is the principal 8-9 nm intermediate filament in mature astrocytes of the central nervous system (CNS). Over a decade ago, the value of GFAP as a prototype antigen in nervous tissue identification and as a standard marker for fundamental and applied research at an interdisciplinary level was recognized (Raine, 135). As a member of the cytoskeletal protein family, GFAP is thought to be important in modulating astrocyte motility and shape by providing structural stability to astrocytic processes. In the CNS of higher vertebrates, following injury, either as a result of trauma, disease, genetic disorders, or chemical insult, astrocytes become reactive and respond in a typical manner, termed astrogliosis. Astrogliosis is characterized by rapid synthesis of GFAP and is demonstrated by increase in protein content or by immunostaining with GFAP antibody. In addition to the major application of GFAP antisera for routine use in astrocyte identification in the CNS, the molecular cloning of the mouse gene in 1985 has opened a new and rich realm for GFAP studies. These include antisense, null mice, and numerous promoter studies. Studies showing that mice lacking GFAP are hypersensitive to cervical spinal cord injury caused by sudden acceleration of the head have provided more direct evidence for a structural role of GFAP. While the structural function of GFAP has become more acceptable, the use of GFAP antibodies and promoters continue to be valuable in studying CNS injury, disease, and development.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11059815     DOI: 10.1023/a:1007677003387

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  378 in total

Review 1.  Biomaterial Approaches to Modulate Reactive Astroglial Response.

Authors:  Jonathan M Zuidema; Ryan J Gilbert; Manoj K Gottipati
Journal:  Cells Tissues Organs       Date:  2018-12-05       Impact factor: 2.481

2.  Effects of chronic guanosine treatment on hippocampal damage and cognitive impairment of rats submitted to chronic cerebral hypoperfusion.

Authors:  Marcelo Ganzella; Enderson Dias Alves de Oliveira; Daniel Diniz Comassetto; Fernanda Cechetti; Victor Hermes Cereser; Júlia Dubois Moreira; Gisele Hansel; Roberto Farina Almeida; Denise Barbosa Ramos; Yanier Nuñes Figueredo; Debora Guerini Souza; Jean Pierre Oses; Paulo Valdeci Worm; Matilde Achaval; Carlos Alexandre Netto; Diogo Onofre Souza
Journal:  Neurol Sci       Date:  2011-12-14       Impact factor: 3.307

3.  Drug screening to identify suppressors of GFAP expression.

Authors:  Woosung Cho; Michael Brenner; Noel Peters; Albee Messing
Journal:  Hum Mol Genet       Date:  2010-06-10       Impact factor: 6.150

4.  A one-step dual-labeling method for antigen detection in mast cells.

Authors:  D Menétrey; D Dubayle
Journal:  Histochem Cell Biol       Date:  2003-10-24       Impact factor: 4.304

5.  Astroglial proteins as diagnostic markers of acute intracerebral hemorrhage-pathophysiological background and clinical findings.

Authors:  Robert Brunkhorst; Waltraud Pfeilschifter; Christian Foerch
Journal:  Transl Stroke Res       Date:  2010-08-28       Impact factor: 6.829

Review 6.  Review: microglia of the aged brain: primed to be activated and resistant to regulation.

Authors:  D M Norden; J P Godbout
Journal:  Neuropathol Appl Neurobiol       Date:  2013-02       Impact factor: 8.090

7.  Subchronic oral administration of Benzo[a]pyrene impairs motor and cognitive behavior and modulates S100B levels and MAPKs in rats.

Authors:  Erica Santos Maciel; Regina Biasibetti; Ana Paula Costa; Paula Lunardi; Rebeca Vargas Antunes Schunck; Gabriela Curbeti Becker; Marcelo Dutra Arbo; Eliane Dallegrave; Carlos Alberto Gonçalves; Paulo H Nascimento Saldiva; Solange Cristina Garcia; Rodrigo Bainy Leal; Mirna Bainy Leal
Journal:  Neurochem Res       Date:  2014-03-02       Impact factor: 3.996

8.  Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease.

Authors:  Marianna Sikorska; Patricia Lanthier; Harvey Miller; Melissa Beyers; Caroline Sodja; Bogdan Zurakowski; Sandhya Gangaraju; Siyaram Pandey; Jagdeep K Sandhu
Journal:  Neurobiol Aging       Date:  2014-04-02       Impact factor: 4.673

9.  How relevant are GFAP autoantibodies in autism and Tourette Syndrome?

Authors:  Nikki J Kirkman; Jane E Libbey; Thayne L Sweeten; Hilary H Coon; Judith N Miller; Edward K Stevenson; Janet E Lainhart; William M McMahon; Robert S Fujinami
Journal:  J Autism Dev Disord       Date:  2007-06-20

10.  Hyperconvolution of the inner limiting membrane in vitreomaculopathies.

Authors:  D R J Snead; N Cullen; S James; A V Poulson; A H C Morris; A Lukaris; J D Scott; A J Richards; M P Snead
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-10-07       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.